From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.
1. Introduction - p. Page ix 2. List of Illustrations - p. Page x 3. List of Tables - p. Page xi 4. Chapter 1 : When to Refer a Patient for CAR T-Cell Therapy - p. Page xi 5. Chapter 2 : Optimizing the Apheresis Product∗ - p. Page 6 6. Chapter 3 : CAR T-Cell: Cell Processing Laboratory Considerations∗ - p. Page 16 7. Chapter 4 : Peri-CAR T-Cell Management - p. Page 26 8. Chapter 5 : Management of Cytokine Release Syndrome - p. Page 40 9. Chapter 6 : Special Considerations for ICU Management of Patients Receiving CAR Therapy - p. Page 62 10. Chapter 7 : Neurotoxicities After CAR T-Cell Immunotherapy - p. Page 77 11. Chapter 8 : Hematologic and Non-CRS Toxicities - p. Page 101 12. Chapter 9 : Response Assessment and Post–CAR T-Cell Therapy Management - p. Page 111 13. Chapter 10 : Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR T-Cell Therapy* - p. Page 126 14. Chapter 11 : Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas - p. Page 134 15. Chapter 12 : CAR T-Cell Therapy for CNS Malignancies - p. Page 153 16. Chapter 13 : CAR 2.0: The Next Generation of Synthetic Receptor–Based Cellular Therapy for Cancer - p. Page 188 17. Chapter 14 : Regulatory Issues in Gene-Modified Immune Effector Cell Therapy - p. Page 205 18. Index - p. Page 220
No hay muestra disponible
No hay ficha técnica disponible
From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.
1. Introduction - p. Page ix 2. List of Illustrations - p. Page x 3. List of Tables - p. Page xi 4. Chapter 1 : When to Refer a Patient for CAR T-Cell Therapy - p. Page xi 5. Chapter 2 : Optimizing the Apheresis Product∗ - p. Page 6 6. Chapter 3 : CAR T-Cell: Cell Processing Laboratory Considerations∗ - p. Page 16 7. Chapter 4 : Peri-CAR T-Cell Management - p. Page 26 8. Chapter 5 : Management of Cytokine Release Syndrome - p. Page 40 9. Chapter 6 : Special Considerations for ICU Management of Patients Receiving CAR Therapy - p. Page 62 10. Chapter 7 : Neurotoxicities After CAR T-Cell Immunotherapy - p. Page 77 11. Chapter 8 : Hematologic and Non-CRS Toxicities - p. Page 101 12. Chapter 9 : Response Assessment and Post–CAR T-Cell Therapy Management - p. Page 111 13. Chapter 10 : Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR T-Cell Therapy* - p. Page 126 14. Chapter 11 : Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas - p. Page 134 15. Chapter 12 : CAR T-Cell Therapy for CNS Malignancies - p. Page 153 16. Chapter 13 : CAR 2.0: The Next Generation of Synthetic Receptor–Based Cellular Therapy for Cancer - p. Page 188 17. Chapter 14 : Regulatory Issues in Gene-Modified Immune Effector Cell Therapy - p. Page 205 18. Index - p. Page 220
No hay muestra disponible
No hay ficha técnica disponible
